Abstract
Research over the past decade has provided convincing evidence to support the premise that phytochemicals from the diet offer protection against cancer risk. A large number of dietary phytochemicals have been demonstrated to exhibit anticancer activities by interfering with multiple signaling pathways aberrant in cancer. These agents target a plethora of cellular molecules and molecular pathways including xenobiotic-metabolizing enzymes, reactive oxygen species, inflammation, cell cycle, apoptosis, invasion, angiogenesis, transcription factors, and protein kinases. In addition, dietary phytochemicals also synergize with conventional chemotherapy and radiotherapy. Thus naturally derived phytochemicals could play an important role in cancer chemoprevention and therapy owing to multitargeted mechanistic action and lack of substantial toxicity. However, more rationally designed novel clinical trials are required to translate the preclinical findings into tangible clinical benefits
Keywords: Chemoprevention, dietary agents, molecular targets, multitargeted prevention, phytochemicals, cancer, plethora of cellular molecules, xenobiotic-metabolizing enzymes, reactive oxygen species, inflammation, apoptosis, invasion, angiogenesis, transcription factors, protein kinases
Current Pharmaceutical Biotechnology
Title: Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Volume: 13 Issue: 1
Author(s): Ramamurthi Vidya Priyadarsini and Siddavaram Nagini
Affiliation:
Keywords: Chemoprevention, dietary agents, molecular targets, multitargeted prevention, phytochemicals, cancer, plethora of cellular molecules, xenobiotic-metabolizing enzymes, reactive oxygen species, inflammation, apoptosis, invasion, angiogenesis, transcription factors, protein kinases
Abstract: Research over the past decade has provided convincing evidence to support the premise that phytochemicals from the diet offer protection against cancer risk. A large number of dietary phytochemicals have been demonstrated to exhibit anticancer activities by interfering with multiple signaling pathways aberrant in cancer. These agents target a plethora of cellular molecules and molecular pathways including xenobiotic-metabolizing enzymes, reactive oxygen species, inflammation, cell cycle, apoptosis, invasion, angiogenesis, transcription factors, and protein kinases. In addition, dietary phytochemicals also synergize with conventional chemotherapy and radiotherapy. Thus naturally derived phytochemicals could play an important role in cancer chemoprevention and therapy owing to multitargeted mechanistic action and lack of substantial toxicity. However, more rationally designed novel clinical trials are required to translate the preclinical findings into tangible clinical benefits
Export Options
About this article
Cite this article as:
Vidya Priyadarsini Ramamurthi and Nagini Siddavaram, Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868610
DOI https://dx.doi.org/10.2174/138920112798868610 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Putative Breast Tumor Suppressor TACC2 Suppresses the Aggressiveness of Breast Cancer Cells through a PLCγ Pathway
Current Signal Transduction Therapy Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Self-Organizing Map (SOM) and Support Vector Machine (SVM) Models for the Prediction of Human Epidermal Growth Factor Receptor (EGFR/ ErbB-1) Inhibitors
Combinatorial Chemistry & High Throughput Screening <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Radiobromine-Labelled Tracers for Positron Emission Tomography: Possibilities and Pitfalls
Current Radiopharmaceuticals Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Fiber Optic Sensors for Biomedical Applications
Current Analytical Chemistry Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) Cancer and Treatment Modalities
Current Cancer Therapy Reviews Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Twenty-Eight Years Survival with Metastatic Phaeochromocytoma Treated by Repeated [131I] Metaiodobenzylguanidine Therapy
Current Radiopharmaceuticals P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design